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The bulk of randomized trial evidence for the expanding use of High Flux (HF) hemodialysis
worldwide comes from two randomized controlled trials, one of which (HEMODIALYSIS,
HEMO) allowed, while the other (Membrane Outcomes Permeability, MPO) excluded, the
reuse of membranes. It is not known whether dialyzer reuse has a differential impact on out-
comes with HF vs low flyx (LF) dialyzers.
Methods
Proportional Hazards Models and Joint Models for longitudinal measures and survival out-
comes were used in HEMO to analyze the relationship between β2-microglobulin (β2M)
concentration, flux, and reuse. Meta-analysis and regression techniques were used to syn-
thesize the evidence for HF dialysis from HEMO and MPO.
Findings
In HEMO, minimally reused (< 6 times) HF dialyzers were associated with a hazard ratio
(HR) of 0.67 (95% confidence interval, 95%CI: 0.48–0.92, p = 0.015), 0.64 (95%CI: 0.44 –
0.95, p = 0.03), 0.61 (95%CI: 0.41 – 0.90, p = 0.012), 0.53 (95%CI: 0.28 – 1.02, p = 0.057)
relative to minimally reused LF ones for all cause, cardiovascular, cardiac and infectious
mortality respectively. These relationships reversed for extensively reused membranes (p
for interaction between reuse and flux < 0.001, p = 0.005) for death from all cause and car-
diovascular causes, while similar trends were noted for cardiac and infectious mortality (p of
interaction between reuse and flux of 0.10 and 0.08 respectively). Reduction of β2M ex-
plained only 1/3 of the effect of minimally reused HF dialyzers on all cause mortality, while
non-β2M related factors explained the apparent attenuation of the benefit with more exten-
sively reused dialyzers. Meta-regression of HEMO and MPO estimated an adjusted HR of
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0.63 (95% CI: 0.51–0.78) for non-reused HF dialyzers compared with non-reused LF
membranes.
Conclusions
This secondary analysis and synthesis of two large hemodialysis trials supports the wide-
spread use of HF dialyzers in clinical hemodialysis over the last decade. A mechanistic un-
derstanding of the effects of HF dialysis and the reuse process on dialyzers may suggest
novel biomarkers for uremic toxicity and may accelerate membrane technology innovations
that will improve patient outcomes.
Introduction
Patients with end-stage renal disease (ESRD) undergoing maintenance hemodialysis (HD)
have a high mortality rate despite continuous improvements in technology and dialytic care
[1]. Worldwide 60% of patients are dialyzed with High Flux (HF) dialyzers. These dialyzers fa-
cilitate the removal of toxins larger than urea [2], based on observational and epidemiologic
studies [3–7] suggesting a clinical benefit from their use. Nevertheless, a Cochrane meta-analy-
sis of ten randomized controlled trials (RCTs) on 2915 patients has shown a benefit of HF
dialysis on cardiovascular mortality but not on all-cause mortality [8]. In this meta-analysis,
the majority of patients (85%), events (96.5%) and thus, the overwhelming evidential weight
(96.1%) for or against the benefits of HF dialysis comes from two RCTs; i.e. HEMODIALYSIS,
(HEMO) [8] and the Membrane Permeability Outcome, (MPO) [9]; which yielded numerically
different estimates for the effect of HF membranes on survival.
Dialyzer reuse, was permitted only in HEMO [9,10] and is considered a key interventional
difference between the two RCTs of HF dialysis [11,12]. Therefore reuse has been offered as
one potential explanation for the somewhat divergent findings of these two studies. Neverthe-
less, an assessment of the impact of reuse on outcomes of HF dialysis in HEMO has not been
performed to date. Such an assessment may inform technology use decisions worldwide, as HF
membranes are the de-facto dialysis industry standard. Reuse of HF membranes is still prac-
ticed in the US [13] and is widely employed in resource limited settings [14,15] providing a jus-
tification for revisiting the effects of reuse on outcomes in HEMO
The major objective of this work is to explore the associations of non-reused and minimally
reused HF v.s. LF dialyzers in the context of HEMO andMPO. Secondarily we were interested to
assess these effects in the medically important subgroups of patients with hypo-albuminemia or
diabetes.To describe the relative role of β2-microglobulin (β2M) concentration, membrane flux
and reuse on patient outcomes in HEMO, we supplemented conventional survival analyses with
emerging techniques for the simultaneous (joint) modeling of patient level biomarkers and sur-
vival. Meta-regression techniques were used to assess the impact of non-reused HF dialyzers
simultaneously considering the evidence in both HEMO andMPO. Finally, we undertook simu-
lations of patient survival under various scenarios of reuse and adoption of HF dialysis.
Subjects and Methods
Subjects and Data
We used the patient level data from the HEMO RCT of the effects of HD dose and membrane
flux [16] as distributed by the National Institute of Diabetes and Digestive and Kidney Diseases
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(NIDDK). Data are available from the NIDDK repository website http://www.niddkrepository.
org. We classified HEMO participants into cohorts of increasing reuse, based on monthly col-
lected dialysis information. Patients were assigned to the most commonly observed reuse
method in their study records since the same reuse technique was utilized in over 92% of the
sessions for the vast majority (85%) of the study patients. Patients were classified as dialyzed
with non-reused membranes, if the number of reuses for their dialyzer was zero for every
monthly dialysis session in the study records. We used a two-step procedure to classify all
other patients to cohorts of increasing dialyzer reuse. At the first step we computed the 97.5th
quartile for the number of reuses for each study participant during the entire study period. Sub-
sequently, these individual measures of reuse exposure were grouped into quartiles. In addi-
tion, the cumulative mean number of filter reuses was computed on a monthly basis for each
patient and was used for sensitivity analyses in survival and Joint Models. We carried out this
sensitivity analysis to ensure that the results were robust to our approach of assigning reuse.
β2M clearance was calculated with a variable-volume single-pool model, adjusted for the fluid
removal during dialysis [17,18].
The Institutional Review Board (IRB) of the University of New Mexico approved this sec-
ondary analysis of the HEMO Randomized Controlled Trial (Study ID 13–468 decision of 12/
12/2013). All study participants had provided informed consent to participate in HEMO, and
the ethics committees/IRBs of participating centers had reviewed and approved the consent
form during protocol review. These documents and the HEMO can be downloaded from the
NIDDK repository. Individual HEMO participants were not consented for this secondary anal-
ysis, because the data as distributed by the NIDDK has been de-identified. Furthermore the
data use agreement between the investigators of this paper and NIDDK prohibits us from mak-
ing any contact to identify individuals, families or communities. The IRB of the University of
New Mexico waived the requirement for an informed consent for this secondary analysis after
reviewing the original consent form that HEMO participants signed upon their enrollment, the
data use agreement between the investigators and NIDDK and the associated research protocol
submitted to the NIDDK.
Statistical Methods
Survival Modeling. We applied the proportional hazard (Cox) model to compute hazard
ratios (HRs) in patient cohorts. These models were adjusted for all baseline covariates used in
the initial trial report: Kt/V arm assignment, age, gender, presence of diabetes, race, co-morbid-
ity score (ICED), duration of ESRD, serum albumin level, dialysis dose (Kt/V arm assignment)
and flux. We also adjusted survival models for vascular access and residual urine output in
order to minimize residual confounding from omitting these prognostically important vari-
ables. The role of dialysis access is well established as a predictor of survival in the nephrology
literature (e.g. in the USRDS US registry[19], the Renal Disease Registry in Ontario[20] and
the international comparisons in the DOPPS registry[21]). We have previously found access to
be a confounder in statistical analysis of the CHOICE prospective dialysis cohort in the US
[22], while more recently access was found to modify the risk associated with dialysis in for-
profit v.s. non-for-profit dialysis units in the US[23]. Residual renal function (RRF) has been
found to be a predictor of survival in studies from the Netherlands (NECOSAD-2)[24], in the
US[25] and even in the context of incremental dialysis[26]. It is a topic of re-emerging impor-
tance in the dialysis literature (see [27]for an excellent review). To account for clustering of di-
alysis patients in units, we computed robust (sandwich) standard error estimates in all Cox
models. This methodology[28], has been become the de facto standard for analyzing hemodial-
ysis outcomes (see[29–33] for indicative, non-exhaustive list of references) since its initial
Dialyzer Reuse and High Flux Dialysis
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introduction. Patient’s follow-up time was censored if they were alive at the end of the study or
when they received a kidney transplant, but not when they dropped out from the study in ac-
cordance with the HEMO statistical analysis plan [9].
Repeated Measures Modeling. We related β2M clearance to the extent of reuse with
mixed effect models that employed a nested, individual-within-center random effect structure
for the correlation between repeated measures obtained in the same individual. Generalized Es-
timating Equations (GEEs) for binary outcomes were used to analyze the membrane material
(polysulfone vs. non-polysulfone). The use of the two different repeated measures methodolo-
gies is justified by the design of the HEMO study and our research questions. In particular, the
HEMO protocol tracked clearance of beta 2 microglobulin at the patient level. Therefore to an-
alyze the relevant variables (beta 2 microglobulin and clearance) an individual level approach
such as a (generalized) linear mixed model is indicated. On the other hand, HEMO did not en-
force the use of specific membrane materials on a patient or a study center level, so that analyz-
ing the population exposures becomes the relevant question. GEEs implement population level
models, and are the appropriate methodology to use for our research question[34].
Joint Modeling of predialysis β2M concentration, and survival. We characterized the re-
lationship between flux, β2M concentration, and survival using a joint model (JM) [35] for re-
peated measures and survival. A JM is an analytical method for the simultaneous estimation of
treatment effects on survival outcomes, the effects of treatment on the concentration of a bio-
marker over time (trajectory function) and the independent effects of the latter on survival.
Since other factors may affect survival either directly or indirectly (through the biomarker con-
centration) the JM may adjust for them to reduce residual confounding. The JM overcomes the
biases implied by the simplistic inclusion of time updated values of biomarkers in survival
models. These biases which arise from measurement error and informative censoring (e.g. lack
of measurements after patient’s death) may seriously compromise the inferences of the survival
models[36,37]. The interpretation of the fitted joint model assigns direct treatment effects (not
associated with changes in the biomarker i.e. β2M trajectory and indirect treatment effects (as-
sociated with changes in the biomarker concentration and the effects of the latter on survival).
The overall treatment effect (measured in the log-hazard scale) is the sum of the direct and in-
direct effects (Fig 1) [38–40] and is usually not different from the one estimated by the Cox
model.
To describe the trajectory of β2M over time in HEMO we used a natural cubic spline with
internal knots at 45 and 90 days and two external knots at 0 days (beginning of the study) and
6 months after randomization. The adopted specification allowed flexible modeling of a) the
non-linear changes in β2M concentration, resulting from changing membrane flux in the six
months post-randomization, followed by a b) linear trend afterwards. The justification for this
bi-phasic model was based on previous clinical investigations [41–45] and computer simula-
tions [46–48], demonstrating that changes in serum β2M concentration occur within a few
weeks after abrupt changes in dialytic clearance with very little change thereafter. As patients
in HEMO could be dialyzed either with LF or HF before randomization, we allowed the trajec-
tory of β2M concentration to differ according to both pre-randomization and post-randomiza-
tion membrane flux. Hence our model anticipated increases or decreases in β2M concentration
(e.g. patients switching from HF to LF membranes and vice versa) and stable β2M trajectories
(e.g. patients who were randomly assigned to the same flux as the filters used prior to study
enrollment).
The selection of the position of the internal knots was motivated by the sampling frequency
of predialysis β2M concentration in HEMO: β2M was measured on the first and second month
and then every other month (HF arm) and at months 1, 4 and yearly thereafter (LF arm).
Hence, we specified the position of the internal knots to ensure that sufficient data points were
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available at each interval (0–45 days, 45–90 days, 90–180 days and 180 days-end of follow up)
for the estimation of the spline coefficients. Of note, only a small number of HEMO study par-
ticipants (<10%) had β2M determinations at baseline and these measurements were included
in the dataset that was supplied to the JM.
We utilized the capability of JMs to yield dynamic, subject specific survival probabilities
from a baseline set of measurements [31] in order to predict the expected outcomes (difference
in 5 year survival probability) under all possible flux and reuse combinations that were utilized
in HEMO (S1 Text: Simulations). These simulations allow us to predict the effects of reusing ei-
ther LF or HF dialyzers in a cohort of patients with similar characteristics to the HEMO study
participants. These are Bayesian probability estimates which do not admit a conventional p-
value calculation for their comparison. Hence, we adopted the literature convention, and con-
sidered differences in survival as “significant” if the corresponding 95% Credible Interval (CrI,
Fig 1. Conceptual depiction of the Joint Modeling Framework. A joint model is an analytical method for the simultaneous estimation of treatment effects
on survival outcomes, the effects of treatment on the concentration of a biomarker over time (trajectory function) and the effects of the latter on survival. As
the true biomarker level is unobserved, a JM has to reconstruct its trajectory before these effects can be estimated. Other factors may affect survival either
directly or indirectly (through the biomarker concentration) and they can be used to adjust a JM and thus reduce residual confounding. One possible
interpretation of the fitted joint model effects on survival assigns direct treatment effects (not associated with changes in the biomarker trajectory, α) and
indirect treatment effects (associated with changes in the biomarker concentration, given by the product of β and γ). Hence, the overall treatment effect in the
Hazard Ratio scale is the (exponentiated) sum of direct and indirect effects. This effect is usually numerically similar to the one estimated by a Cox model.
doi:10.1371/journal.pone.0129575.g001
Dialyzer Reuse and High Flux Dialysis
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the range of values in which 95% of the probability is contained) excludes zero. Further techni-
cal details about the JM are given in S1 Text.
Evidence Synthesis of HEMO and MPO. HEMO and MPO are the largest prospective
RCTs of membrane flux, accounting for>96% of the total weight of evidence in a recent
Cochrane Group Systematic Review of the impact of HF dialyzers on outcomes [8]. The afore-
mentioned meta-analysis did not account for differences in reuse, patient demographics, dialy-
sis dose or statistical adjustments for baseline patient characteristics that were employed in
HEMO and MPO (S1 Text). To account for the differences in interventions, patients in HEMO
were cross-classified according to the single-pool Kt/V (spKt/V) arm(coded as standard or
high), flux and quartiles of reuse, before computing discrete outcomes (number of events and
patient years) for unadjusted meta-analyses. Since the average dialysis dose employed in MPO
was similar to the standard dose employed in HEMO, all patients fromMPO were classified as
receiving standard dialysis with either LF or HF membranes. To align the statistical models
used in the trials, we re-analyzed survival in HEMO using the same statistical model that the
MPO investigators used in their report. Investigators in MPO, adjusted the hazard ratio of flux
for age, Kt/V, gender, diabetes, comorbidity score and type of access. This information was ex-
tracted from the MPO publication (Table 4 in [19]). We applied the same model in HEMO to
yield adjusted estimates for high flux dialysis within each of the eight cohorts defined on the
basis of reuse quartile and Kt/V assignment. To combine the adjusted hazard ratios from both
studies, we utilized random effects meta-regression. Meta-regression adjusted these flux esti-
mates for spKt/V and the average reuse number of the patients in each HEMO reuse quartile.
As dialyzers were not reused in MPO, the corresponding reuse number was set to zero.
We also undertook subgroup analysis in hypoalbuminemic patients (a prespecified sub-
group in the MPO analytic protocol). Secondary analyses of the MPO and other observational
datasets [6] suggest that diabetic patients may derive an additional benefit from HF dialysis.
Consequently, we also considered a subgroup analysis of the diabetic study participants in the
two studies. Further technical details about the meta-analysis are given in Supplementary
Methods (S1 Text, Section: “Meta-analysis and Meta-regression of HEMO and MPO”).
All statistical analyses were performed with R versions 2.9.2–2.15.1; joint modeling was un-
dertaken with the R package “JM” version 1.0–1.1 [34,35].
Results
Patients and Reuse Exposures
Characteristics of patients were similar across quartiles of reuse with the exception of patients
of white race and female gender who were more likely to be represented in the lowest reuse
quartile (Table 1). As a group, patients at the lowest reuse quartile were also more likely to be
enrolled later in the trial, to be dialyzed with HF dialyzers before randomization and to have re-
sidual urine output (Table 1). However, within reuse quartiles there were no substantial differ-
ences in characteristics in patients randomized to LF versus HF membranes (S1–S4 Tables).
There was no statistically significant difference in the odds of using polysulfone vs. non-poly-
sulfone dialyzers between the two flux arms in the first (Odds Ratio (OR): 0.88, 95%CI: 0.60–
1.27), p = 0.48) and across the remaining reuse quartiles (p for the interaction between flux and
2nd -4th quartiles: 0.21, 0.66, 0.27). The most common reuse method involved peracetic acid
(PAA, 45.3% of patients), followed by formaldehyde (FAH, 25.1%), gluteraldehyde (GAH,
10.7%) and heated citric acid (HCA, 9.4%); only a minority (9.5%) of all HEMO patients were
dialyzed with non-reused filters.
The method (S5 Table) and extent of reuse differed among different dialyzers, ranging from
10.9 ± 5.6 (PAA) to 15.2 ± 5.0 (FAH) times in accordance with the labeling information of the
Dialyzer Reuse and High Flux Dialysis
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dialyzers and dialysis center practices. Mixed model analysis demonstrated wide differences in
the average clearance of reused HF dialyzers by reuse method: 2.72±1.13 ml/min (FAH,
p = 0.016), -1.26±1.31 ml/min (GAH, p = 0.33), 5.71±1.35 ml/min (HCA, p<0.001), -12.9±1.1
ml/min (PAA, p<0.001), relative to non-reused ones (38.4±0.97 ml/min).
The average predialysis β2M concentration in patients dialyzing with non-reused HF mem-
branes was 31.1 ± 0.99 mg/l; β2M was non-significantly increased by FHA, GAH or HCA re-
processing: 1.57 ± 1.15 mg/l (p = 0.17), 1.59 ± 1.39 mg/l (p = 0.23), 1.54 ± 1.40 mg/l (p = 0.27)
respectively. Only reprocessing with PAA was associated with a moderately higher β2M
Table 1. Baseline Characteristics of HEMO Participants by Reuse Quartile.
Reuse Quartile p
N 531 443 448 404
Range of Number of Reuses 0–6 7–12 13–17 >17
Flux Assignment 0.59
High Flux 48% (254) 48% (213) 52% (234) 52% (209)
Kt/V Assignment 0.27
High Kt/V 50% (268) 53%(236) 48%(216) 47%(190)
Prerandomization Membrane Flux <0.001
High Flux 47% (246) 66% (289) 59% (264) 72% (289)
Age 58 ± 14 58 ± 14 58 ± 13 57 ± 15 0.90
Race <0.001
Black 56% (300) 72% (321) 62% (279) 60% (244)
Diabetic Status 0.52
Diabetic 44% (234) 46% (205) 46% (207) 42% (169)
Gender 0.33
Female 59% (312) 56% (248) 53% (237) 56% (228) 0.045
Duration (years) 3.43 ± 4.17 3.86 ± 4.44 4.06 ± 4.75 3.71 ± 4.05 0.56
Cause of ESRD
Glomerulonephritis 15% (79) 15% (66) 13% (60) 12% (47)
Hypertension 28% (150) 32% (140) 32% (143) 36% (146)
Diabetes 37% (199) 38% (167) 39% (176) 34% (139)
Ischemic Nephropathy 7% (37) 5% (21) 6% (25) 4% (18)
Acute Renal Disease 4% (22) 3% (12) 1% (6) 2% (10)
Other 9% (44) 7% (37) 9% (38) 12% (44)
Albumin (g/dl) 3.61 ± 0.35 3.63 ± 0.35 3.63 ± 0.37 3.63 ± 0.36 0.66
Residual Renal Function* 0.007
Urine Volume (>200 ml/day) 17% (90) 9% (41) 14% (63) 13% (54)
ICED 1.93 ± 0.84 1.98 ± 0.83 1.93 ± 0.83 2.06 ± 0.82 0.085
Vascular Access
Arteriovenous Fistula 35% (188) 33% (148) 34% (151) 31% (126) 0.27
Arteriovenous Graft 57% (305) 58% (258) 61% (274) 61% (247)
Catheter/Other 7% (38) 8% (37) 5% (23) 7% (31)
Year of Randomization(since the beginning of HEMO) 3.19 ± 1.65 1.69 ± 1.41 1.62 ± 1.53 1.92 ± 1.68 <0.001
Summary statistics are presented as mean ± standard deviation and as % (frequencies) for continuous and categorical variables respectively. Tests used
to compare variables Pearson test (categorical), Kruskal-Wallis (continuous). The total number of patients (1826) differs from the number of patients
enrolled in HEMO, because there was no available information about reuse for 20 subjects who died before their ﬁrst post-enrolment evaluation. ICED:
Index of Coexistent Diseases.
doi:10.1371/journal.pone.0129575.t001
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concentration of 4.03 β2M ± 1.08 mg/l (p<0.001) relative to non-reused HF dialysis in these
unadjusted analyses. After adjusting for a large number of covariates (Kt/V, race, gender, dia-
betes, comorbidity score, duration of dialysis dependency, vascular access, transplantation
status, smoking, BMI, albumin, urine output (as more or less than a cup per day) and study
center, reuse with PAA was not associated with higher β2M concentration (difference of
-0.28 ± 1.65, p = 0.87).
In summary, the potentially large impact of reuse method on β2M clearance did not trans-
late into a substantial effect on predialysis β2M concentration. As the HEMO study protocol
controlled the maximum number of reuses, according to the effects of reuse protocol on clear-
ance, the average β2M clearance did not materially differ across reuse quartiles (Fig 2).
Relative effect of HF dialysis on survival depends on the extent of
dialyzer reuse
The effects of HF dialysis were modified by the extent of dialyzer reuse. In adjusted Cox models
(S6 Table), the interaction between flux and reuse was statistically significant for all-cause
(p<0.001) and cardiovascular (p = 0.005) mortality. A trend for higher relative mortality for
cardiac and infectious causes (p = 0.10 and p = 0.08 for the interaction between HF and reuse)
was also noticed. These statistical interactions imply that a beneficial effect of HF relative to LF
dialysis on all-cause and cause-specific mortality was attenuated for patients dialyzed with fil-
ters that were reused more than 6 times (Table 2). Sensitivity analyses, which used the time up-
dated (cumulative mean) number or reuses did not yield substantially different HR estimates
(S7 Table). In analyses adjusting for reuse method, the interaction between flux and extent of
reuse remained significant. In these analyses, FAH and GAH were associated with numerically
worse relative outcomes to other reuse methods (not shown). There was no interaction
Fig 2. Distribution of predicted β2M clearance across quartiles of membrane reuse in HEMO.
Controlling the extent of reuse by the HEMO study protocol yielded average clearances that were equivalent
across reuse quartiles in patients receiving HF dialysis. Average β2M clearance by HF dialyzers in the 2nd to
4th reuse quartile, was 1.26±1.02 (p = 0.21), 1.47±1.00 (p = 0.14) and 5.41±1.03 (p<0.001) ml/min higher
relative to the first quartile (31.8±0.69 ml/min).
doi:10.1371/journal.pone.0129575.g002
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between reuse, baseline urine production and dialysis flux (p for all three way interactions>
0.77) suggesting that the effects of reuse and flux did not differ between anuric patients and
those with minimal RRF.
When interactions between albumin concentration at baseline and HF dialysis were exam-
ined, we noted a statistically significant effect for cardiac (p = 0.009), and a trend for cardiovas-
cular and all-cause mortality (p = 0.051 and p = 0.096 respectively). The direction of the
interaction term indicates a larger benefit of HF dialysis for patients with lower albumin levels.
No interaction was noted between the presence of diabetes at baseline and all-cause or cause
specific mortality (p>0.20 for all interactions).
To better understand these findings we undertook a number of joint modeling analyses aim-
ing to ascertain whether reuse a) affected the exposure to middle molecules (β2M concentra-
tion) b) whether the association of a given β2M concentration with survival differed according
to the extent of dialyzer reuse and c) whether the apparent attenuation of the protective effect
of HF dialysis reflected worse outcomes with reused high flux membranes or improved survival
in patients exposed to reused LF dialyzers.
The effects of reuse on outcomes of HF dialysis are not related to middle
molecules
Dialyzer reuse is not associated with differential changes in β2M concentration. In the
first six months of HEMO, β2M increased in patients assigned to LF membranes and decreased
in patients assigned to the HF arm (Table 3, acute slope); the rate of change of β2M was smaller
after the first six months (Table 3, chronic slope). The rate of accumulation of β2M in patients
exposed to reused LF membranes was smaller by 1.01 to 2.01 mg/l/year compared to the non-
reused membranes. Rates of accumulation of β2M did not differ between HF and LF mem-
branes subjected to the same extent of reuse (p: 011–0.98 Table 3). Differences in the concen-
tration of β2M between the HF and LF arms were established early and maintained throughout
the duration of the study (Fig 3). Adjusted mean differences (SE) in predialysis β2M concentra-
tion between LF and HF dialysis were not materially different in the various reuse quartiles:
-8.29(0.99), -9.68(1.22), -6.73(1.06), -8.42(1.27) mg/dl for 0–6, 7–12, 12–17,>17 reuses
respectively.
Changes in β2M account only partly for the effects of non-reused HF dialyzers. In joint
models, serum β2M concentration was a statistically significant predictor of survival: each 10
mg/L elevation was associated with an estimated HR of 1.16 (95% CI: 1.07–1.25, p<0.001). In-
direct effects of HF vs. LF dialysis (i.e. those associated with changes in serum β2M) were not
Table 2. Hazard Ratio of Death for All Cause and Cause Specific mortality between High Flux and Low Flux Dialysis versus extent of Reuse.
1st Quartile (N = 526) 2nd Quartile (N = 436) 3rd Quartile (N = 438) 4th Quartile (N = 403)
Number of Reuses 0–6 6–12 12–17 >17
All Cause Mortality 0.67 (0.48–0.92) p = 0.015 0.86 (0.66–1.12) p = 0.27 0.86 (0.64–1.14) p = 0.29 1.45 (1.13–1.86) p = 0.003
Cardiac Mortality 0.64 (0.44–0.95) p = 0.03 0.69 (0.44–1.08) p = 0.10 0.83 (0.55–1.26) p = 0.37 0.98 (0.68–1.41) p = 0.91
Cardiovascular Mortality 0.61 (0.41–0.90) p = 0.012 0.62 (0.40–0.95) p = 0.029 0.81 (0.55–1.20) p = 0.30 1.16 (0.88–1.54) p = 0.29
Infectious Mortality 0.53 (0.28–1.02) p = 0.057 1.11 (0.69–1.81) p = 0.66 0.64 (0.35–1.18) p = 0.16 1.30 (0.85–1.99) p = 0.22
Hazard Ratio (HR) estimates were obtained from a Cox regression model adjusting for reuse quartile, ﬂux and Kt/V assignments, age, sex, diabetes,
duration of ESRD dependency (upon study enrolment), ICED, albumin, vascular access, pre-randomization ﬂux, residual urine volume, and ﬁnally the
interaction between reuse quartile and ﬂux; the baseline hazard was stratiﬁed by study centre. Reported Relative Risks are model predictions and
associated 95% CI for patients dialyzed with high ﬂux relative to patients dialyzed with low ﬂux, reused to the same extent as the former. Results based on
1803 patients with complete data for model ﬁtting.
doi:10.1371/journal.pone.0129575.t002
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different across reuse quartiles (Table 4) and were moderate in magnitude (hazard ratios rang-
ing from 0.87–0.91). On the other hand, direct effects, i.e. not explained by changes in predialy-
sis β2M, differed across reuse quartiles and in fact reversed direction for highly reused
membranes (Table 4). Total effects of flux were nearly identical to the results of the Cox models
in Table 2 (not shown).
Similar findings were obtained when reuse was treated as a time updated variable in sensi-
tivity analyses: the best fitting JM suggested a quadratic relationship between the direct and
total effects of flux and HR of death so that the hazard ratio was increased in patients receiving
HF dialysis when these dialyzers were reused more than 17 times (S1 Fig). In sensitivity analy-
ses, the attained β2M concentration did not have a differential association with survival in pa-
tients treated with reused HF dialyzers (p for the interaction between indirect effect and flux,
indirect effect and cumulative reuse and flux by cumulative reuse: 0.28, 0.10 and 0.25
respectively).
Reuse is not associated with worse outcomes in HF dialysis, but improves outcomes in
patients exposed to LF membranes. We used JMs to predict absolute survival in a cohort of
simulated patients who were exposed to the 8 different combinations of flux and quartiles of
reuse. Irrespective of the extent of their reuse, HF membranes are predicted to confer a survival
advantage over minimally reused LF dialyzers, e.g. a 9.9% increase in 5 year survival (95% CrI:
1.6%-18.0%) and 9.2% (95% CrI: 1.3–19.4%) for the lowest and highest reuse quartiles respec-
tively. However, compared to minimal reuse of HF dialyzers, extensive reuse of these mem-
branes was not associated with worsening survival, i.e a difference in five year survival
probability of -0.7% (95% CrI -10.5% to 6.2% for the highest reuse quartile vs. minimal reuse).
The neutral effect of reuse on outcomes of HF dialysis was also evident in the Kaplan Meier
Table 3. Average Acute (first six months) and Chronic Slopes (> 6 months) of Predialysis β2M Concentration according to Reuse Quartile and
Membrane Flux.
Acute Slope (0–6 months) Chronic Slope (>6 months)
Reuse Estimate (SE) Pǂ P* Estimate (SE) Pǂ P*
Low Flux
0–6 6.61 (1.77) Ref Ref 2.27 (0.37) Ref Ref
7–12 -1.49 (2.71) 0.58 Ref -1.56 (0.49) 0.002 Ref
13–17 1.50 (2.65) 0.57 Ref -2.01 (0.49) <0.001 Ref
>17 0.46 (2.94) 0.89 Ref -1.07 (0.50) 0.003 Ref
High Flux
0–6 -5.44 (1.77) Ref <0.001 1.54 (0.28) Ref 0.11
7–12 4.66 (2.67) 0.081 0.004 -0.51 (0.38) 0.17 0.49
13–17 5.00 (2.52) 0.047 0.001 -1.26 (0.37) <0.001 0.98
>17 5.06 (2.85) 0.076 0.021 -0.45 (0.43) 0.28 0.78
Estimates of slopes are given in Δmg/L β2M/year relative to the ﬁrst quartile of reuse in each ﬂux arm (entry in rows labelled “0–6”); all estimates were
obtained by a joint model for the (untransformed) β2M concentration and survival. The longitudinal and survival submodels adjusted for reuse quartile, ﬂux
and Kt/V assignments, age, sex, diabetes, duration of ESRD dependency (upon study enrolment), ICED, albumin, vascular access, pre-randomization
ﬂux, residual urine volume, study center and the interaction between reuse quartile by ﬂux. To model the changing trajectories of β2M as a result of
patients being assigned to dialyzers with a different ﬂux than the one used before randomization, the longitudinal component also included interactions
between pre- and post-randomization ﬂux and a spline function of time since randomization. The baseline hazard of the survival submodel was modeled
with a natural spline with two internal knots at 45 and 90 days and two boundary (external) knots at 0 and 180 days.
ǂP-values comparing each slope to the reference category within each ﬂux arm * P value comparing the slope between the same reuse category of the
two ﬂux arms.
doi:10.1371/journal.pone.0129575.t003
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Fig 3. Predicted predialysis β2M concentrations across reuse quartiles andmembrane flux in HEMO participants. These predictions were obtained
by fitting a Joint Model to the HEMO dataset which was then used to predict the β2M concentration for the HEMO study participants at different time points.
The panels show the mean and standard deviation obtained by averaging individual level predictions at each time point. Separation between the high (HF)
and the low flux(LF) arms in terms of the β2M concentration were established early in the trial. There was very little difference in the separation of flux arms
across the quartiles of reuse, i.e. estimated difference (SE) in β2M concentration between HF and LF was -8.27 (0.56), -9.67 (1.22), -6.72 (1.06), and -8.42
(1.26) mg/L in the 1st-4th reuse quartiles respectively.
doi:10.1371/journal.pone.0129575.g003
Table 4. Joint Model estimates of Adjusted Hazard Ratios for All Cause Mortality associated with the use of High Flux vs. Low Flux Dialyzers under
different extents of Reuse.
Indirect Effect Direct Effect
Reuse Estimate 95% CI P Estimate 95% CI P
0–6 0.89 0.82–0.95 <0.001 0.78 0.57–1.06 0.12
7–12 0.87 0.80–0.93 <0.001 0.98 0.75–1.28 0.88
13–17 0.91 0.85–0.96 <0.001 0.98 0.75–1.28 0.87
>17 0.88 0.82–0.95 <0.001 1.72 1.28–2.32 <0.001
Hazard Ratio (HR) estimates were obtained from a Joint Model for pre-dialysis β2M (untransformed) and all cause-mortality as detailed in the methods
and the legend of Table 3. Reported Hazard Ratios and associated 95% CI for patients dialyzed with HF are relative to patients dialyzed with LF ones,
reused to the same extent as the HF ones.
doi:10.1371/journal.pone.0129575.t004
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curves which were nearly superimposable (Fig 4). On the other hand, reuse of LF membranes
modified survival (Fig 4) especially; the highest five year survival probability was noted for the
most extensively reused LF dialyzers: 55.6% (95% CrI: 49.3–61.4%).
From a comparative effectiveness perspective, these simulations imply that the effects of HF
dialysis in a given reuse setting would depend on the extent of the reuse and the referent (LF vs.
HF). In HEMO, reuse of low flux dialyzers was associated with improved absolute clinical out-
comes in the LF arm, but was not associated with either worse or improved outcomes in the
HF arm. These patterns underlie the apparent attenuation of the hazard ratio of high flux dialy-
sis with reuse (Table 2)
Synthesis of HEMO and MPO results suggests a benefit for non-reused/minimally re-
used HF dialyzers that may be larger in hypoalbuminemic patients. When synthesizing the
evidence from the adjusted analyses of HEMO and MPO without accounting for the extent of
reuse or small molecule clearance, we obtained results compatible with the ones reported in the
unadjusted meta-analysis by the Cochrane group [8]: HR for all cause mortality of 0.89, 95%
CI (0.71–1.11, p = 0.28, S2 Fig panel A) vs. 0.95 (95% CI: 0.87–1.04, p = 0.23[32]). In meta-
analysis of adjusted HRs, HF dialysis was associated with a statistically significant effect in the
subgroup of hypoalbuminemic patients (HR: 0.70, 95%CI: 0.52–0.93, p = 0.013, S2 Fig, panel
B) but not those with diabetes (HR: 0.87, 95%CI: 0.68–1.11, p = 0.26, S2 Fig, panel C).
In meta-regression analyses, both linear and quadratic relationships between flux and num-
ber of reuses were examined, with the later providing better fit to the data (S1 Text: Supple-
mentary Results). Model predictions for the HR of HF dialysis for different number of reuses
and standard Kt/V dialysis dose are shown in Fig 5; the model predicts an adjusted HR of 0.63
(95% CI: 0.51–0.78) for HF dialysis with non-reused membranes, with the relative effects of
flux progressively weaning after the 7th reuse. When we examined outcomes in patients with
hypo-albuminemia and in diabetics we obtained similar results: a model predicted HR of 0.56,
Fig 4. Predicted survival curves obtained by dynamic simulations of Joint Models. These were derived
by counterfactually exposing HEMO study participants to all possible flux and reuse combinations. Individual
survival probability curves were averaged at each observation point and these population averaged curves
are depicted separately for low flux(LF) and high flux(HF) dialysis. Five year survival probabilities (P5,
estimate and 95%Credible Interval) were as follows: 33.8% (28.0%-39.4%), 36.1% (30.8%-41.0%), 42.4%
(36.9%-47.8%) and 55.6% (49.3%-55.8%) for increasing reuse of LF membranes. P5 (estimates and 95%
Credible Intervals) for increasing reuse of HF dialyzers were: 43.7% (37.4%-49.1%), 38.% (32.9%-43.5%),
44.8% (38.1%-50.7%) and 43.0% (37.0%-49.1%).
doi:10.1371/journal.pone.0129575.g004
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(95% CI: 0.36–0.86, p = 0.009) and HR of 0.64 (95% CI: 0.46–0.89, p = 0.008) respectively asso-
ciated with HF dialysis with non-reused dialyzers (graphs not shown). When we considered
only the HEMO participants dialyzed with non-reused membranes, the results were consistent
with the meta-regressions in showing a protective effect of HF dialysis that was numerically
higher in hypo-albuminemic and diabetic patients (Fig 6).
Discussion
In this secondary analysis of HEMO we found that minimally reused HF filters were associated
with reduction in the hazard ratio for all-cause and cause-specific mortality relative to their LF
counterparts, but this relation reversed at high levels of reuse. In joint modeling analyses of sur-
vival and predialysis β2M levels we found that this mortality pattern was not associated with
differential effects on β2M concentration by reused dialyzers i.e. an indirect effect of flux. Evi-
dence synthesis of the HEMO and MPO, the largest randomized trials to date to explore the ef-
fects of HF dialysis, support the beneficial effect of minimally reused HF dialyzers while
suggesting a higher benefit for hypo-albuminemic patients and possibly for diabetics.
Our finding of a 25–30% relative risk reduction for patients dialyzed with minimally reused
HF dialyzers appears plausible as it is consistent with multiple sources of data. Specifically, our
numerical estimate is nearly equal to the effects of HF dialysis in MPO (in which reuse was not
permitted) and is also in line with existing observational studies [21] that were used in the de-
sign of HEMO [8,25] and MPO [36]. Furthermore, the reduction in all-cause mortality is driv-
en by reductions in cardiac and cardiovascular mortality. This pattern is consistent with
multiple non-randomized analyses of the outcomes of HF dialysis [3,5–7,38]. In addition, the
effects of HF dialysis appear larger in magnitude among hypo-albuminemic and diabetic pa-
tients in whom previous pre-specified RCT [10] and post-hoc [6] observational analyses have
Fig 5. Predicted Hazard Ratio (HR) of High Flux(HF) dialysis as a function of membrane reuse.
Predictions were obtained by fitting a meta-regression model to adjusted (for age, gender, diabetes, vascular
access and comorbidity score) HR of subgroups of HEMO (defined on the basis of reuse quartiles, Kt/V and
flux) and MPO. The meta-regression model accounted for Kt/V and the (square) of the extent of reuse. Of
note, reuse of HF membranes up to 13 times appears to yield a protective effect with a predicted RR of 0.83,
and an associated 95% CI: 0.70–0.99 that excludes unity.
doi:10.1371/journal.pone.0129575.g005
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respectively suggested a larger benefit. Lastly, our meta-analysis of HEMO and MPO, which ac-
counts for the differences in dialysis dose and reuse, shows a consistent benefit of non-reused
and minimally reused HF dialyzers effects on all-cause mortality. Our simulation analyses uti-
lizing the HEMO dataset predict that the adoption of HF dialysis in the US may have contrib-
uted to the 25% relative decline in mortality of the prevalent hemodialysis population seen
over the last 15 years [49].
A tacit assumption made by investigators considering the overall null results of HEMO
[10,50] is that reuse somehow render higher flux dialyzers less effective compared to their non-
reused counterparts. Our analysis of the HEMO data does find an association between reuse
and dialyzer flux, but in the opposite direction: rather than negatively affecting the survival of
patients dialyzing with reused HF membranes, reuse improved the outcomes of LF dialysis. To
our knowledge this is the first analysis to highlight the importance of the extent of reuse and
membrane flux in addition to membrane material and reprocessing technique [51] on out-
comes The existing literature includes harmful [51–54], protective [55] or null associations
[13,56] and an overall neutral effect on mortality across the various studies [57]. The conflict-
ing nature of the literature seems hardly surprising given the numerous factors that could con-
found the relation between reuse and outcomes. In particular, one could posit that reuse may
be affecting RRF, an underappreciated but powerful predictor of survival in hemodialysis
[24,26,27,58–60]. This hypothesis seems unlikely as an explanation for the associations we re-
ported in HEMO, since the study enrolled patients with minimal RRF (urea clearance<0.5 ml/
min) and most patients (67%) were anuric at baseline. Hence, an analysis of reuse on residual
diuresis over time is limited by the small number of study participants that simultaneously had
non-negligible urine output at baseline and follow up. Previous investigators have looked into
the question of changes in RRF and beta 2 microglobulin in HEMO [61] and concluded that
“rigorous modeling the rate of decline in residual kidney function is prohibited because the ma-
jority of patients had no measurable residual kidney clearance at baseline”.
To better understand the effects of HF dialysis on outcomes in the HEMO Study, we jointly
modeled survival and β2M concentration in study participants. This novel analysis suggests
that changes in β2M concentration explain one third of the estimated benefit of minimally re-
used HF dialyzers, while the remainder is accounted for by direct effects which are not related
to β2M. Thus, in spite of the theoretical predominance of the “middle molecule” hypothesis on
dialysis technology research[62], a closer examination of HEMO suggests that removal of these
uremic solutes may have only a modest effect on outcomes. Although β2M is considered a
marker for the entire spectrum of “middle”molecule toxins [63,64], other uremic retention sol-
utes may demonstrate dialytic kinetics that differ from those of β2M [65,66]. It is conceivable
that the direct flux effect, could be ascribed to an imprecise quantification of middle molecule
exposure by the predialysis β2M concentration, the removal of other molecules or to non-clear-
ance effects of dialyzers. Recent work by our group shows that the predialysis β2M concentra-
tion is an accurate measure of the time averaged concentration of β2M[67,68], so that the first
hypothesis appears unlikely. Although research to date has largely focused on β2M kinetics
[69] and its involvement in dialysis related amyloidosis, the knowledge gap in the field of ure-
mic toxicity does not rule out the possibility i.e. the direct effect of flux is HEMO is mediated
through the clearance of non-β2M “large” molecules. However, this appears a less likely expla-
nation since the clearance of these molecules by HF dialyzers is smaller than the clearance of
Fig 6. Meta-analysis of adjusted Hazard Ratio in HEMO study participants dialyzed with non-reused
HFmembranes and MPO patients. (A) all patients, (B) hypo-albuminemic patients, (C) patients
with diabetes.
doi:10.1371/journal.pone.0129575.g006
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urea and β2M which were both controlled by HEMO. Consequently, the possibility that reused
membranes exhibit differential kinetics of elimination is more theoretical than real. Even if dif-
ferential kinetics of large molecules was they play, the latter would have to exhibit an improba-
ble combination of high threshold for toxicity (otherwise patients would not survive long
enough to be enrolled in HEMO) and an extremely adverse toxicity profile after the threshold
(otherwise a differential effect would not be observed in HEMO). These considerations argue
that non-clearance attributes of dialyzers explain the direct effects of flux and its modification
by reuse.
An insight into the processes underlying the direct effects of flux and the effects of reuse
comes from our dynamic outcomes simulations in which reuse had a striking modulating effect
on LF but not on HF dialysis. Compared to non-reused LF membranes, reused ones were asso-
ciated with improved survival, while reusing HF dialyzers had essentially no impact on surviv-
al. As dialyzer reuse [70] is generally [71–73], but not invariably [74–76] associated with
enhanced biocompatibility and reduced oxidative stress, it would be tempting to speculate that
this discrepancy can be attributed to an improvement in biocompatibility seen only with reuse
of LF dialyzers. However, a selective increase in the biocompatibility of LF dialyzers by reuse
appears unlikely for a number of reasons. Firstly, bioincompatible membranes were prohibited
in HEMO [9,16] ruling out a difference in the ex-factory biocompatibility between HF and LF
dialyzers. Furthermore, had a selective reuse-related improvement in biocompatibility oc-
curred, one would expect this to be associated with reduced production rates of inflammatory
biomarkers (including β2M [73]) only with LF dialysis [71]. In a study, such as HEMO, of func-
tionally anephric patients in which middle molecule clearance is stably controlled by protocol,
higher rates of β2M production would be associated with progressive accumulation over time.
However reuse v.s non-reuse decreased the chronic slope in the β2M concentration to a similar
extent in the two study arms. Therefore, if biocompatibility was improved by reuse, it probably
did so to the same extent for LF and HF membranes. This conclusion is compatible with a pre-
vious report in a subgroup of patients from HEMO which showed that reuse improved phago-
cytic cell function (an index of membrane biocompatibility [77,78]) irrespective of membrane
flux [79]. Taken together these considerations suggest that reuse improved biocompatibility of
both LF and HF dialyzers in HEMO but additional factors have to be invoked to explain the
lack of outcome improvement with reuse of HF dialyzers.
Previous assessments of HF dialyzers [80–84] by morphometric (via Atomic Force and
Transmission Electron Microscopy), protein elution and immunoblotting methods have re-
vealed alterations in morphology (increased pore size, cracking) and protein deposition in the
dialysate side of the HF membranes associated with first use and subsequent reuses. These pro-
teins with a molecular weight< 30kDa correspond to middle molecules that had been filtered
in previous dialysis sessions with the same membrane and could (along with chemical residues
from the fractured membrane material) theoretically been back-filtered to the patient during
subsequent dialysis sessions. As such proteins are not filtered at all by LF membranes the com-
bination of previous deposition in the internal (dialysate side), enhanced permeability and
back filtration of previously filtered middle molecules could offer an attractive explanation of
the differential effects of reuse on outcomes with HF and LF membranes.
The use of HF dialyzers is now widespread worldwide [2] and will increase further as con-
vective therapies (hemodiafiltration/hemofiltration) that require these filters become estab-
lished through evidence from randomized trials [85–87]. Our analysis of reuse in HEMO and
the synthesis of HEMO and MPO have implications for nephrology practice. In the developed
world, where reuse of dialyzers is either prohibited by law (European Union and Japan) or not
practiced as a result of operational protocols (the majority of the dialysis providers in the
USA), we suggest that LF membranes should be abandoned in favor of HF dialyzers. To the
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extent that HF dialyzer reuse is a necessary component of a dialysis program for environmental
[57], financial (e.g. other dialysis providers in the USA) [88] or resource constraint (as in lower
income countries) [14,76,89,90] reasons, we believe that reused HF dialyzers may realize the
same benefits over non-reused LF dialyzers and thus HF membranes should also be preferred.
Though extensive reuse of LF dialyzers is unlikely to ever be practiced except in severely re-
source-constrained settings, our re-exploration of HEMO suggests that there may be upsides in
not adopting HF dialysis in these environments. Furthermore, in such systems substantial pro-
portion of dialysis units lack proper water treatment facilities [14,89] making the use of HF
membranes risky as a result of backfiltration [91,92], while the reduced (usually biweekly) dial-
ysis frequency limits the cumulative removal of middle molecules.
These findings should be interpreted in light of the following limitations. First, our analysis is
a secondary one, suitable for generating hypothesis for further studies. HEMOwas not designed
to test the effects of non-reused HF dialyzers, hence we cannot rule out the possibility of chance
underlying the beneficial effects of non-reused to slightly reused HF dialyzers. Nevertheless, a
large number of confounding factors, which could have conceivably affected outcomes assess-
ment (including baseline urine production), did not differ between the two flux arms within
reuse quartiles. Furthermore, a patient level meta-analysis between HEMO andMPO should be
undertaken to corroborate the impression that the flux effect appears to be larger in patients with
hypo-albuminemia and diabetes while examining the cardiovascular and infectious components
of mortality. Such an analysis could also consider the residual renal function and its evolution
over time in both studies in order to explore the combined dialytic/residual renal clearance on
outcomes. Second, the reason for the apparent attenuation in relative survival of patients dialyzed
with HF dialyzers cannot be discerned from this report. As this attenuation does not appear to be
related to β2M concentration or clearance, analyzing the HEMO samples in the NIDDK biobank
repository [93,94] could offer some insights about a putative biocompatibility benefit limited
only to LF membranes or the backfiltration hypothesis we endorse.
As the largest study of dialyzer flux in chronic hemodialysis patients, the HEMO Study find-
ings have strongly influenced patient care and are referenced by the US [95], UK Renal Associa-
tion [96], European Best Practice Guidelines on Hemodialysis Strategies [97], and the Australian
Hemodialysis Clinical Guidelines [98]. This work provides a more detailed examination of vari-
ability of outcomes related to dialyzer reuse in HEMO. Our analysis uncovers hitherto unrecog-
nized compatibilities in the findings of HEMO andMPO with respect to the overall effects of
non-reused HF dialyzers, but also in the clinically important subgroups of hypo-albuminemic
and diabetic patients. As these two studies contribute the bulk of RCT evidence for or against
higher permeability membranes, our analysis may allow for a more precise appraisal of the avail-
able body of data justifying the widespread use of HF dialyzers. Furthermore, this analysis rein-
forces the recent guideline updates [98,99] which endorse the use of HF membranes in clinical
practice. Future examination of longitudinal changes in biomarkers in previously established bio-
repositories and of physicochemical properties of membranes may be able to pinpoint the non-
clearance factors that explain the effects of dialyzer flux. Finally such an examination will suggest
novel ways to materialize technological innovations to further improve patient outcomes.
Supporting Information
S1 Fig. Results of JM in which reuse was treated as continuous, time updated variable. The
longitudinal and survival sub models were adjusted for the same variables as in Table 4; the
panels (in clockwise order) show the relative reduction in β2M six months after the beginning
of the study and the corresponding indirect, direct and total effects of HF dialysis as a function
of the cumulative number of reuses. The relative reduction in predialysis β2M concentration
Dialyzer Reuse and High Flux Dialysis
PLOS ONE | DOI:10.1371/journal.pone.0129575 June 9, 2015 17 / 23
was only minimally affected by reuse, while the direct and consequently the total effect of HF
dialysis was related to the extent of reuse. Relative to LF dialyzers, HF membranes were associ-
ated with reduced hazard ratio of death as long as they were reused for less than 8 times, while
reuse of HF dialyzers for more than 17 times was associated with relative increases in mortality
(HR>1).
(TIFF)
S2 Fig. Meta-analysis of adjusted (for diabetes, vascular access, comorbidity score, age, gen-
der) HR of HF dialysis between HEMO and MPO. In the meta-analysis of HEMO and MPO
a substantial amount of heterogeneity across the range of membrane reuse and small molecule
clearance used in the two studies was noted: Q = 20.4, p(Q) = 0.009. (A) all patients, (B)
hypoalbuminemic patients, (C) patients with diabetes.
(TIFF)
S1 Table. Baseline Characteristics of HEMO participants in the lowest reuse quartile
(DOC)
S2 Table. Baseline Characteristics of HEMO participants in the second reuse quartile
(DOC)
S3 Table. Baseline Characteristics of HEMO participants in the third reuse quartile
(DOC)
S4 Table. Baseline Characteristics of HEMO participants in the highest reuse quartile
(DOC)
S5 Table. Dialyzer Reuse Method Combinations used in HEMO participants
(DOC)
S6 Table. Survival Analysis in HEMO with Cox models incorporating reuse by flux interac-
tions
(DOC)
S7 Table. Hazard Ratio of Death between HF and LF dialysis versus extent of reuse adjust-
ing for time of randomization. In these models, the cumulative mean number of reuses (avail-
able monthly for each patient) was used.
(DOC)
S1 Text. Supplementary Methods and Results
(DOC)
Acknowledgments
TheHEMODIALYSIS (HEMO) study was conducted by theHEMO Investigators and sup-
ported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The
data from theHEMO study were supplied by the NIDDK Central Repositories. This manu-
script was not prepared in collaboration with Investigators of theHEMO study and does not
necessarily reflect the opinions or views of theHEMO study, the NIDDK Central Repositories,
or the NIDDK.
Author Contributions
Conceived and designed the experiments: MER CAMLU. Analyzed the data: CA. Contributed
reagents/materials/analysis tools: LW AS. Wrote the paper: CA MER AS LW JAKMLU.
Dialyzer Reuse and High Flux Dialysis
PLOS ONE | DOI:10.1371/journal.pone.0129575 June 9, 2015 18 / 23
Obtained permission for use of the data: MLU. Advised on statistical methodologies: LW. Pro-
grammed early version of statistical analysis software used to verify some of the results: AS.
Simulation modelling of outcomes: CA.
References
1. Rocco MV, Frankenfield DL, Hopson SD, McClellan WM. Relationship between clinical performance
measures and outcomes among patients receiving long-term hemodialysis. Annals of internal medi-
cine. 2006; 145: 512–9. PMID: 17015869
2. Blankestijn PJ, Ledebo I, Canaud B. Hemodiafiltration: clinical evidence and remaining questions. Kid-
ney Int. 2010; 77: 581–7. doi: 10.1038/ki.2009.541 PMID: 20130529
3. BloembergenWE, Hakim RM, Stannard DC, Held PJ, Wolfe RA, Agodoa LY, et al. Relationship of dial-
ysis membrane and cause-specific mortality. Am J Kidney Dis. 1999; 33: 1–10. PMID: 9915261
4. Chauveau P, Nguyen H, Combe C, Chene G, Azar R, Cano N, et al. Dialyzer membrane permeability
and survival in hemodialysis patients. Am J Kidney Dis. 2005; 45: 565–71. PMID: 15754279
5. Koda Y, Nishi S, Miyazaki S, Haginoshita S, Sakurabayashi T, Suzuki M, et al. Switch from convention-
al to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis pa-
tients. Kidney Int. 1997; 52: 1096–1101. PMID: 9328951
6. Krane V, Krieter DH, Olschewski M, Marz W, Mann JF, Ritz E, et al. Dialyzer membrane characteristics
and outcome of patients with type 2 diabetes on maintenance hemodialysis. Am J Kidney Dis. 2007;
49: 267–75. PMID: 17261429
7. Hornberger JC, ChernewM, Petersen J, Garber AM. A multivariate analysis of mortality and hospital
admissions with high-flux dialysis. J Am Soc Nephrol. 1992; 3: 1227–37. PMID: 1477318
8. Palmer SC, Rabindranath KS, Craig JC, Roderick PJ, Locatelli F, Strippoli GFM. High-flux versus low-
flux membranes for end-stage kidney disease. Cochrane Database of Systematic Reviews. 2012;9.
Available: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005016.pub2/abstract
9. Greene T, Beck GJ, Gassman JJ, Gotch FA, Kusek JW, Levey AS, et al. Design and Statistical Issues
of the Hemodialysis (HEMO) Study. Controlled Clinical Trials. 2000; 21: 502–525. doi: 10.1016/S0197-
2456(00)00062-3 PMID: 11018567
10. Locatelli F, Martin-Malo A, Hannedouche T, Loureiro A, Papadimitriou M, Wizemann V, et al. Effect of
membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol. 2009; 20: 645–54. doi:
10.1681/ASN.2008060590 PMID: 19092122
11. Cheung AK, Greene T. Effect of membrane permeability on survival of hemodialysis patients. J Am Soc
Nephrol. 2009; 20: 462–4. doi: 10.1681/ASN.2009010030 PMID: 19211709
12. Locatelli F, Gauly A, Czekalski S, Hannedouche T, Jacobson SH, Loureiro A, et al. The MPO Study:
just a European HEMO Study or something very different? Blood purification. 2008; 26: 100–4. doi: 10.
1159/000110574 PMID: 18182806
13. Bond TC, Nissenson AR, Krishnan M, Wilson SM, Mayne T. Dialyzer reuse with peracetic acid does
not impact patient mortality. Clin J Am Soc Nephrol. 2011; 6: 1368–74. doi: 10.2215/CJN.10391110
PMID: 21566107
14. Jha V. Current status of end-stage renal disease care in South Asia. Ethn Dis. 2009; 19: S1–27–32.
15. Tiranathanagul K, Susantitaphong P, Keomany C, Mahatanan N, Praditpornsilpa K, Eiam-Ong S.
Long-term efficacy of pre- and post-dilution online hemodiafiltration with dialyzer reuse. J Med Assoc
Thai. 2012; 95: 650–6. PMID: 22994023
16. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, et al. Effect of Dialysis Dose
and Membrane Flux in Maintenance Hemodialysis. N Engl J Med. 2002; 347: 2010–2019. doi: 10.1056/
NEJMoa021583 PMID: 12490682
17. Leypoldt JK, Cheung AK, Deeter RB. Single compartment models for evaluating beta 2-microglobulin
clearance during hemodialysis. ASAIO J. 1997; 43: 904–909. PMID: 9386841
18. Cheung AK, Agodoa LY, Daugirdas JT, Depner TA, Gotch FA, Greene T, et al. Effects of hemodialyzer
reuse on clearances of urea and beta2-microglobulin. The Hemodialysis (HEMO) Study Group. J Am
Soc Nephrol. 1999; 10: 117–27. PMID: 9890317
19. Schon D, Blume SW, Niebauer K, Hollenbeak CS, de Lissovoy G. Increasing the Use of Arteriovenous
Fistula in Hemodialysis: Economic Benefits and Economic Barriers. CJASN. 2007; 2: 268–276. doi: 10.
2215/CJN.01880606 PMID: 17699424
20. McQuillan R, Trpeski L, Fenton S, Lok CE. Modifiable Risk Factors for Early Mortality on Hemodialysis.
International Journal of Nephrology. 2012; 2012: e435736. doi: 10.1155/2012/435736
Dialyzer Reuse and High Flux Dialysis
PLOS ONE | DOI:10.1371/journal.pone.0129575 June 9, 2015 19 / 23
21. Pisoni RL, Arrington CJ, Albert JM, Ethier J, Kimata N, KrishnanM, et al. Facility Hemodialysis Vascular
Access Use and Mortality in Countries Participating in DOPPS: An Instrumental Variable Analysis.
American Journal of Kidney Diseases. 2009; 53: 475–491. doi: 10.1053/j.ajkd.2008.10.043 PMID:
19150158
22. Argyropoulos C, Chang C- CH, Plantinga L, Fink N, Powe N, Unruh M. Considerations in the statistical
analysis of hemodialysis patient survival. J Am Soc Nephrol. 2009; 20: 2034–2043. doi: 10.1681/ASN.
2008050551 PMID: 19643932
23. Brunelli SM, Wilson S, Krishnan M, Nissenson AR. Confounders of mortality and hospitalization rate
calculations for profit and nonprofit dialysis facilities: analytic augmentation. BMC Nephrol. 2014; 15:
121. doi: 10.1186/1471-2369-15-121 PMID: 25047925
24. Termorshuizen F, Dekker FW, van Manen JG, Korevaar JC, Boeschoten EW, Krediet RT. Relative
Contribution of Residual Renal Function and Different Measures of Adequacy to Survival in Hemodialy-
sis Patients: An analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECO-
SAD)-2. JASN. 2004; 15: 1061–1070. doi: 10.1097/01.ASN.0000117976.29592.93 PMID: 15034110
25. Shemin D, Bostom AG, Laliberty P, Dworkin LD. Residual renal function and mortality risk in hemodialy-
sis patients. Am J Kidney Dis. 2001; 38: 85–90. doi: 10.1053/ajkd.2001.25198 PMID: 11431186
26. Vilar E, Wellsted D, Chandna SM, Greenwood RN, Farrington K. Residual renal function improves out-
come in incremental haemodialysis despite reduced dialysis dose. Nephrol Dial Transplant. 2009; 24:
2502–2510. doi: 10.1093/ndt/gfp071 PMID: 19240122
27. Vilar E, Farrington K. Emerging importance of residual renal function in end-stage renal failure. Semin
Dial. 2011; 24: 487–494. doi: 10.1111/j.1525-139X.2011.00968.x PMID: 21999737
28. Lin DY, Wei LJ. The Robust Inference for the Cox Proportional Hazards Model. Journal of the American
Statistical Association. 1989; 84: 1074–1078. doi: 10.1080/01621459.1989.10478874
29. Seliger SL, Gillen DL, Longstreth WT, Kestenbaum B, Stehman-Breen CO. Elevated risk of stroke
among patients with end-stage renal disease. Kidney Int. 2003; 64: 603–609. doi: 10.1046/j.1523-
1755.2003.00101.x PMID: 12846756
30. Udayaraj UP, Ben-Shlomo Y, Roderick P, Steenkamp R, Ansell D, Tomson CRV, et al. Ethnicity, Socio-
economic Status, and Attainment of Clinical Practice Guideline Standards in Dialysis Patients in the
United Kingdom. Clin J Am Soc Nephrol. 2009; 4: 979–987. doi: 10.2215/CJN.06311208 PMID:
19357243
31. Badve SV, Hawley CM, McDonald SP, Mudge DW, Rosman JB, Brown FG, et al. Effect of previously
failed kidney transplantation on peritoneal dialysis outcomes in the Australian and New Zealand patient
populations. Nephrol Dial Transplant. 2006; 21: 776–783. doi: 10.1093/ndt/gfi248 PMID: 16280374
32. Lafrance J-P, Rahme E, Iqbal S, Elftouh N, Laurin L-P, Vallée M. Trends in infection-related hospital ad-
missions and impact of length of time on dialysis among patients on long-term dialysis: a retrospective
cohort study. cmajo. 2014; 2: E109–E114. doi: 10.9778/cmajo.20120027 PMID: 25077126
33. Inrig JK, Sun JL, Yang Q, Briley LP, Szczech LA. Mortality by Dialysis Modality among Patients Who
Have End-Stage Renal Disease and Are Awaiting Renal Transplantation. CJASN. 2006; 1: 774–779.
doi: 10.2215/CJN.00580705 PMID: 17699286
34. Gardiner JC, Luo Z, Roman LA. Fixed effects, random effects and GEE: what are the differences? Stat
Med. 2009; 28: 221–239. doi: 10.1002/sim.3478 PMID: 19012297
35. Rizopoulos D. Joint Models for Longitudinal and Time-to-Event Data: With Applications in R [Internet].
Chow S-C, editor. CRC Press; 2012. Available: http://www.crcpress.com/product/isbn/
9781439872864 http://www.crcpress.com/product/isbn/9781439872864
36. Kalbfleisch JD, Prentice RL. Likelihood Construction and Further Results. The Statistical Analysis of
Failure Time Data. JohnWiley & Sons, Inc.; 2002. pp. 193–217. Available: http://onlinelibrary.wiley.
com/doi/10.1002/9781118032985.ch6/summary
37. Fisher LD, Lin DY. Time-Dependent Covariates in the Cox Proportional-Hazards Regression Model.
Annual Review of Public Health. 1999; 20: 145–157. doi: 10.1146/annurev.publhealth.20.1.145 PMID:
10352854
38. De Gruttola V, Tu XM. Modelling progression of CD4-lymphocyte count and its relationship to survival
time. Biometrics. 1994; 50: 1003–14. PMID: 7786983
39. Wulfsohn MS, Tsiatis AA. A joint model for survival and longitudinal data measured with error. Bio-
metrics. 1997; 53: 330–9. PMID: 9147598
40. Faucett CL, Thomas DC. Simultaneously modelling censored survival data and repeatedly measured
covariates: a Gibbs sampling approach. Stat Med. 1996; 15: 1663–85. PMID: 8858789
41. Santoro A, Mancini E, Bolzani R, Boggi R, Cagnoli L, Francioso A, et al. The effect of on-line high-flux
hemofiltration versus low-flux hemodialysis on mortality in chronic kidney failure: a small randomized
controlled trial. Am J Kidney Dis. 2008; 52: 507–18. doi: 10.1053/j.ajkd.2008.05.011 PMID: 18617304
Dialyzer Reuse and High Flux Dialysis
PLOS ONE | DOI:10.1371/journal.pone.0129575 June 9, 2015 20 / 23
42. Mandolfo S, Borlandelli S, Imbasciati E. Leptin and beta2-microglobulin kinetics with three different dial-
ysis modalities. Int J Artif Organs. 2006; 29: 949–55. PMID: 17211816
43. Pellicano R, Polkinghorne KR, Kerr PG. Reduction in beta2-microglobulin with super-flux versus high-
flux dialysis membranes: results of a 6-week, randomized, double-blind, crossover trial. Am J Kidney
Dis. 2008; 52: 93–101. doi: 10.1053/j.ajkd.2008.02.296 PMID: 18423807
44. Lonnemann G, Novick D, Rubinstein M, Passlick-Deetjen J, Lang D, Dinarello CA. A switch to high-flux
helixone membranes reverses suppressed interferon-gamma production in patients on low-flux dialy-
sis. Blood Purif. 2003; 21: 225–231. doi: 10.1159/000070694 PMID: 12784048
45. Mayer G, Thum J, Woloszczuk W, Graf H. Beta-2-microglobulin in hemodialysis patients. Effects of dif-
ferent dialyzers and different dialysis procedures. Am J Nephrol. 1988; 8: 280–4. PMID: 3055992
46. Ward RA, Greene T, Hartmann B, SamtlebenW. Resistance to intercompartmental mass transfer limits
beta2-microglobulin removal by post-dilution hemodiafiltration. Kidney Int. 2006; 69: 1431–1437. doi:
10.1038/sj.ki.5000048 PMID: 16395268
47. Kanamori T, Sakai K. An estimate of beta 2-microglobulin deposition rate in uremic patients on hemodi-
alysis using a mathematical kinetic model. Kidney Int. 1995; 47: 1453–1457. PMID: 7637274
48. Clark WR, Leypoldt JK, Henderson LW, Mueller BA, Scott MK, Vonesh EF. Quantifying the effect of
changes in the hemodialysis prescription on effective solute removal with a mathematical model. J Am
Soc Nephrol. 1999; 10: 601–609. PMID: 10073611
49. USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in
the United States,. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Di-
gestive and Kidney Diseases; 2013.
50. Locatelli F. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med.
2003; 348: 1491–4; author reply 1491–4. PMID: 12691051
51. Feldman HI, Bilker WB, Hackett MH, Simmons CW, Holmes JH, Pauly MV, et al. Association of dialyzer
reuse with hospitalization and survival rates among U.S. hemodialysis patients: do comorbidities mat-
ter? Journal of clinical epidemiology. 1999; 52: 209–17. PMID: 10210238
52. Collins AJ, Ma JZ, Constantini EG, Everson SE. Dialysis unit and patient characteristics associated
with reuse practices and mortality: 1989–1993. J Am Soc Nephrol. 1998; 9: 2108–17. PMID: 9808098
53. Lacson E, WangW, Mooney A, Ofsthun N, Lazarus JM, Hakim RM. Abandoning peracetic acid-based
dialyzer reuse is associated with improved survival. Clin J Am Soc Nephrol. 2011; 6: 297–302. doi: 10.
2215/CJN.03160410 PMID: 20947788
54. Lowrie EG, Li Z, Ofsthun N, Lazarus JM. Reprocessing dialysers for multiple uses: recent analysis of
death risks for patients. Nephrol Dial Transplant. 2004; 19: 2823–30. PMID: 15316099
55. Chuang FR, Lee CH, Chang HW, Lee CN, Chen TC, Chuang CH, et al. A quality and cost-benefit analy-
sis of dialyzer reuse in hemodialysis patients. Ren Fail. 2008; 30: 521–6. doi: 10.1080/
08860220802064747 PMID: 18569933
56. Collins AJ, Liu J, Ebben JP. Dialyser reuse-associated mortality and hospitalization risk in incident
Medicare haemodialysis patients, 1998–1999. Nephrol Dial Transplant. 2004; 19: 1245–1251. doi: 10.
1093/ndt/gfh011 PMID: 14993497
57. Galvao TF, Silva MT, Araujo ME de A, Bulbol WS, Cardoso AL de MP. Dialyzer Reuse and Mortality
Risk in Patients with End-Stage Renal Disease: A Systematic Review. American Journal of Nephrolo-
gy. 2012; 35: 249–258. doi: 10.1159/000336532 PMID: 22353780
58. Penne EL, van der Weerd NC, Blankestijn PJ, van den Dorpel MA, Grooteman MPC, Nubé MJ, et al.
Role of residual kidney function and convective volume on change in beta2-microglobulin levels in
hemodiafiltration patients. Clin J Am Soc Nephrol. 2010; 5: 80–86. doi: 10.2215/CJN.03340509 PMID:
19965537
59. Amici G, Virga G, Da Rin G, Grandesso S, Vianello A, Gatti P, et al. Serum beta-2-microglobulin level
and residual renal function in peritoneal dialysis. Nephron. 1993; 65: 469–471. PMID: 8290003
60. Van der Wal WM, Noordzij M, Dekker FW, Boeschoten EW, Krediet RT, Korevaar JC, et al. Full loss of
residual renal function causes higher mortality in dialysis patients; findings from a marginal structural
model. Nephrol Dial Transplant. 2011; 26: 2978–2983. doi: 10.1093/ndt/gfq856 PMID: 21317411
61. Cheung AK, Rocco MV, Yan G, Leypoldt JK, Levin NW, Greene T, et al. Serum beta-2 Microglobulin
Levels Predict Mortality in Dialysis Patients: Results of the HEMO Study. J Am Soc Nephrol. 2006; 17:
546–555. doi: 10.1681/ASN.2005020132 PMID: 16382021
62. Vanholder R, Van Laecke S, Glorieux G. The middle-molecule hypothesis 30 years after: lost and redis-
covered in the universe of uremic toxicity? J Nephrol. 2008; 21: 146–160. PMID: 18446708
63. Tattersall J. Clearance of beta-2-microglobulin and middle molecules in haemodiafiltration. Contribu-
tions to nephrology. 2007; 158: 201–9. PMID: 17684359
Dialyzer Reuse and High Flux Dialysis
PLOS ONE | DOI:10.1371/journal.pone.0129575 June 9, 2015 21 / 23
64. Leypoldt JK. Kinetics of beta2-microglobulin and phosphate during hemodialysis: effects of treatment
frequency and duration. Semin Dial. 2005; 18: 401–408. doi: 10.1111/j.1525-139X.2005.00079.x
PMID: 16191181
65. Eloot S, Torremans A, De Smet R, Marescau B, De Deyn PP, Verdonck P, et al. Complex compartmen-
tal behavior of small water-soluble uremic retention solutes: evaluation by direct measurements in plas-
ma and erythrocytes. Am J Kidney Dis. 2007; 50: 279–288. doi: 10.1053/j.ajkd.2007.05.009 PMID:
17660029
66. Eloot S, Dhondt A, Van Landschoot M, Waterloos M-A, Vanholder R. Removal of water-soluble and
protein-bound solutes with reversed mid-dilution versus post-dilution haemodiafiltration. Nephrol Dial
Transplant. 2012; 27: 3278–3283. doi: 10.1093/ndt/gfs060 PMID: 22492823
67. Argyropoulos C, Roumelioti ME, Nolin T, Unruh ML. Systematic Review of Beta 2 Microglobulin Popula-
tion Kinetics. ASN Renal Week. Philadelphia; 2014. p. SA–PO969.
68. Argyropoulos C, Nolin T, Roumelioti ME, Kalantar-Zadeh K, Unruh ML. Large Scale Modeling of Beta 2
Microglobulin Population Kinetics Biomarker for In-silico Hemodialysis Trials. ASN Renal Week. Phila-
delphia; 2014. p. SA–PO970.
69. Eloot S, Van BiesenW, Vanholder R. A sad but forgotten truth: the story of slow-moving solutes in fast
hemodialysis. Semin Dial. 2012; 25: 505–9. doi: 10.1111/j.1525-139X.2012.01107.x PMID: 22925227
70. Upadhyay A, Sosa MA, Jaber BL. Single-use versus reusable dialyzers: the known unknowns. Clin J
Am Soc Nephrol. 2007; 2: 1079–86. PMID: 17702728
71. Hakim RM, Wingard RL, Husni L, Parker RA, Parker TF. The effect of membrane biocompatibility on
plasma beta 2-microglobulin levels in chronic hemodialysis patients. J Am Soc Nephrol. 1996; 7: 472–
478. PMID: 8704114
72. Dumler F, Zasuwa G, Levin NW. Effect of dialyzer reprocessing methods on complement activation
and hemodialyzer-related symptoms. Artif Organs. 1987; 11: 128–31. PMID: 3036049
73. Westhuyzen J, Foreman K, Battistutta D, Saltissi D, Fleming SJ. Effect of dialyzer reprocessing with
Renalin on serum beta-2-microglobulin and complement activation in hemodialysis patients. Am J
Nephrol. 1992; 12: 29–36. PMID: 1415362
74. Klinkmann H, Grassmann A, Vienken J. Dilemma of membrane biocompatibility and reuse. Artif Or-
gans. 1996; 20: 426–432. PMID: 8725623
75. Kuwahara T, Markert M, Wauters JP. Biocompatibility aspects of dialyzer reprocessing: a comparison
of 3 re-use methods and 3 membranes. Clin Nephrol. 1989; 32: 139–143. PMID: 2791365
76. Ramakrishna P, Reddy EP, Suchitra MM, Bitla AR, Rao PV, Sivakumar V. Effect of reuse of polysulfone
membrane on oxidative stress during hemodialysis. Indian J Nephrol. 2012; 22: 200–5. doi: 10.4103/
0971-4065.98758 PMID: 23087556
77. Ward RA. Phagocytic cell function as an index of biocompatibility. Nephrol Dial Transplant. 1994; 9
Suppl 2: 46–56. PMID: 8065617
78. Banche G, Allizond V, Giacchino F, Mandras N, Roana J, Bonello F, et al. Effect of dialysis membrane
biocompatibility on polymorphonuclear granulocyte activity in dialysis patients. Nephrol Dial Transplant.
2006; 21: 3532–3538. doi: 10.1093/ndt/gfl415 PMID: 16935897
79. Rao M, Guo D, Jaber BL, Sundaram S, Cendoroglo M, King AJ, et al. Dialyzer membrane type and
reuse practice influence polymorphonuclear leukocyte function in hemodialysis patients. Kidney Int.
2004; 65: 682–91. PMID: 14717942
80. Cornelius RM, McClungWG, Barre P, Esguerra F, Brash JL. Effects of reuse and bleach/formaldehyde
reprocessing on polysulfone and polyamide hemodialyzers. Asaio J. 2002; 48: 300–11. PMID:
12059006
81. Cornelius RM, McClungWG, Richardson RM, Estridge C, Plaskos N, Yip CM, et al. Effects of heat/citric
acid reprocessing on high-flux polysulfone dialyzers. Asaio J. 2002; 48: 45–56. PMID: 11820220
82. Mulzer SR, Brash JL. Identification of plasma proteins adsorbed to hemodialyzers during clinical use. J
Biomed Mater Res. 1989; 23: 1483–504. PMID: 2621220
83. Sotonyi P, Jaray J, Padar Z, Woller J, Furedi S, Gal T. Comparative study on reused haemodialysis
membranes. Int J Artif Organs. 1996; 19: 387–92. PMID: 8841852
84. Valette P, Thomas M, Dejardin P. Adsorption of low molecular weight proteins to hemodialysis mem-
branes: experimental results and simulations. Biomaterials. 1999; 20: 1621–34. PMID: 10482417
85. GrootemanMPC, van den Dorpel MA, Bots ML, Penne EL, van der Weerd NC, Mazairac AHA, et al. Ef-
fect of online hemodiafiltration on all-cause mortality and cardiovascular outcomes. J Am Soc Nephrol.
2012; 23: 1087–1096. doi: 10.1681/ASN.2011121140 PMID: 22539829
Dialyzer Reuse and High Flux Dialysis
PLOS ONE | DOI:10.1371/journal.pone.0129575 June 9, 2015 22 / 23
86. Maduell F, Moreso F, Pons M, Ramos R, Mora-Macia J, Carreras J, et al. High-efficiency postdilution
online hemodiafiltration reduces all-cause mortality in hemodialysis patients. J Am Soc Nephrol. 2013;
24: 487–97. doi: 10.1681/ASN.2012080875 PMID: 23411788
87. Ok E, Asci G, Toz H, Ok ES, Kircelli F, Yilmaz M, et al. Mortality and cardiovascular events in online
haemodiafiltration (OL-HDF) compared with high-flux dialysis: results from the Turkish OL-HDF Study.
Nephrol Dial Transplant. 2013; 28: 192–202. doi: 10.1093/ndt/gfs407 PMID: 23229932
88. Ahern,Jack. Dialyzer Reuse Redesigned. Renal Business Today. 16 Feb 2012. Available: http://www.
renalbusiness.com/articles/2012/02/dialyzer-reuse-redesigned.aspx. Accessed 29 Mar 2014.
89. Jha V. Current status of end-stage renal disease care in India and Pakistan. Kidney inter, Suppl. 2013;
3: 157. doi: 10.1038/kisup.2013.3
90. Melo NCV, Moyses RMA, Elias RM, Castro MCM. Reprocessing high-flux polysulfone dialyzers does
not negatively impact solute removal in short-daily online hemodiafiltration. Hemodial Int. 2014; doi: 10.
1111/hdi.12126
91. Schiffl H. High-flux dialyzers, backfiltration, and dialysis fluid quality. Semin Dial. 2011; 24: 1–4. doi: 10.
1111/j.1525-139X.2010.00786.x PMID: 21299628
92. Baurmeister U, Travers M, Vienken J, Harding G, Million C, Klein E, et al. Dialysate contamination and
back filtration may limit the use of high-flux dialysis membranes. ASAIO Trans. 1989; 35: 519–522.
PMID: 2597523
93. Pan H, Ardini MA, Bakalov V, Delatte M, Eggers P, Ganapathi L, et al. “What”s in the NIDDK CDR?’—
public query tools for the NIDDK central data repository. Database (Oxford). 2013; bas058.
94. Turner CF, Pan H, Silk GW, Ardini MA, Bakalov V, Bryant S, et al. The NIDDK Central Repository at 8
years—ambition, revision, use and impact. Database (Oxford). 2011; bar043.
95. Clinical Practice Guidelines for Hemodialysis Adequacy, Update 2006. American journal of kidney dis-
eases: the official journal of the National Kidney Foundation. 2006; 48: S2–S90.
96. Mactier R. Clinical Practice Guidelines for Haemodialysis [Internet]. 2007. Available: http://www.
renalassociation.org/guidelines/print/HDfinal050207.pdf
97. Tattersall J, Canaud B, Heimburger O, Pedrini L, Schneditz D, Van BiesenW, et al. High-flux or low-flux
dialysis: a position statement following publication of the Membrane Permeability Outcome study.
Nephrol Dial Transplant. 2010; 25: 1230–1232. doi: 10.1093/ndt/gfp626 PMID: 20028829
98. Kerr PG, Toussaint ND, Kidney Health Australia, Caring for Australasians with Renal Impairment. KHA-
CARI guideline: dialysis adequacy (haemodialysis): dialysis membranes. Nephrology (Carlton). 2013;
18: 485–488. doi: 10.1111/nep.12096 PMID: 23672488
99. Tattersall JE, Ward RA, EUDIAL group. Online haemodiafiltration: definition, dose quantification and
safety revisited. Nephrol Dial Transplant. 2013; 28: 542–550. doi: 10.1093/ndt/gfs530 PMID: 23345621
Dialyzer Reuse and High Flux Dialysis
PLOS ONE | DOI:10.1371/journal.pone.0129575 June 9, 2015 23 / 23
